Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Medicenna Therapeutics Corp (MDNAF)

Medicenna Therapeutics Corp (MDNAF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 26,355
  • Shares Outstanding, K 28,803
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,590 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 13.16
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.07
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 09/24/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7868 +16.29%
on 07/29/19
1.1900 -23.11%
on 08/05/19
-0.3052 (-25.01%)
since 07/16/19
3-Month
0.6111 +49.73%
on 06/03/19
1.7400 -47.41%
on 06/14/19
+0.4067 (+80.01%)
since 05/15/19
52-Week
0.5056 +80.97%
on 04/17/19
1.7400 -47.41%
on 06/14/19
-0.0498 (-5.16%)
since 08/15/18

Most Recent Stories

More News
Medicenna Selects its Lead Immuno-Oncology Clinical Candidate, MDNA19, from its IL-2 Superkine Platform

MDNA19 demonstrates robust efficacy and safety with or without checkpoint inhibitors in preclinical models; Clinical studies expected to commence in 2020

MDNAF : 0.9150 (-0.34%)
MDNA.TO : 1.19 (-2.46%)
Medicenna Receives US $1.9 Million Non-Dilutive Grant Payment

TORONTO and HOUSTON , July 9, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, announced today...

MDNAF : 0.9150 (-0.34%)
MDNA.TO : 1.19 (-2.46%)
MDNA55 Shows Promising Results in Models of Ovarian Cancer

Scientists at the NIH and FDA Demonstrate Impressive Synergy of MDNA55 with Interferons 

MDNAF : 0.9150 (-0.34%)
MDNA.TO : 1.19 (-2.46%)
Medicenna Presents New Preclinical Results For its IL-2 Superkine Platform, MDNA109

- Long Acting MDNA109 provides durable tumor control and strong memory response without further treatment when combined with checkpoint inhibitors

MDNAF : 0.9150 (-0.34%)
MDNA.TO : 1.19 (-2.46%)
Medicenna Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

TORONTO and HOUSTON , May 16, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.  (" Medicenna " or "the Company ") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company,...

MDNAF : 0.9150 (-0.34%)
MDNA.TO : 1.19 (-2.46%)
Medicenna Receives Non-Dilutive Grant Payment

TORONTO and HOUSTON , May 1, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, announced today...

MDNAF : 0.9150 (-0.34%)
MDNA.TO : 1.19 (-2.46%)
Medicenna Reports Third Quarter Fiscal 2019 Financial Results

TORONTO and HOUSTON, TX , Feb. 14, 2019  /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, today...

MDNAF : 0.9150 (-0.34%)
MDNA.TO : 1.19 (-2.46%)
Medicenna Presents Promising Clinical Data from Phase 2b Recurrent Glioblastoma Trial of MDNA55

Strong interim survival trend (15.2 vs 8.5 months) emerging in IL4R positive patients

MDNAF : 0.9150 (-0.34%)
MDNA.TO : 1.19 (-2.46%)
Medicenna Shows Promising Pre-Clinical Results in Solid Tumor Models with its IL-2 Superkine, MDNA109

Magnified IL-2 affinity towards CD122 potently synergizes with checkpoint inhibitors

MDNAF : 0.9150 (-0.34%)
MDNA.TO : 1.19 (-2.46%)
Preliminary Results on MDNA55 and MDNA109 to be Presented at the Immuno-Oncology 360° Conference

TORONTO and HOUSTON , Jan. 24, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced...

MDNAF : 0.9150 (-0.34%)
MDNA.TO : 1.19 (-2.46%)
Trade MDNAF with:

Key Turning Points

2nd Resistance Point 0.9150
1st Resistance Point 0.9150
Last Price 0.9150
1st Support Level 0.9150
2nd Support Level 0.9150

See More

52-Week High 1.7400
Fibonacci 61.8% 1.2685
Fibonacci 50% 1.1228
Fibonacci 38.2% 0.9771
Last Price 0.9150
52-Week Low 0.5056

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar